DGAP-News: Cytos Biotechnology Second Quarter Report 2011
(firmenpresse) - EquityStory AG-News: Cytos Biotechnology AG / Key word(s): Half Year
Results
Cytos Biotechnology Second Quarter Report 2011
28.07.2011 / 07:00
---------------------------------------------------------------------
Cytos Biotechnology Ltd Second Quarter Report 2011 as of June 30, 2011
Summary of important events in Q2 2011
- Update on combined phase I/IIa study with a novel anti-interleukin-1
beta vaccine in patients with type II diabetes mellitus
- Phase IIb results with CYT003-QbG10 for the treatment of allergic
rhinoconjunctivitis published in the Journal 'Clinical and Experimental
Allergy'
- Constitution of the Board of Directors after the Shareholder's Meeting
2011
- Financial summary
in CHF million YTD* 2011 YTD* 2010 Q2 2011 Q2 2010*YTD = year to date January 1 - June 30
Revenue 1.0 21.4 0.4 21.2
Net operating costs (10.3) (14.4) (4.7) (7.5)
Net (loss)/income (10.0) 11.2 (4.7) 15.0
06/30/11 12/31/10
Cash, cash equivalents, 37.5 48.7
financial assets
and trade and other
receivables
Convertible bonds 41.1 41.1
(outstanding nominal value)
Full-time equivalents 73 81
(number)
The complete Second Quarter Report 2011 can be downloaded on Cytos
Biotechnology's website under the following link:
http://www.cytos.com/userfiles/file/Cytos_Q2_2011_E.pdf
For more information please contact:
Harry Welten, MBA
Chief Financial Officer
Cytos Biotechnology Ltd
Wagistrasse 25, Postfach
CH-8952 Schlieren (Zurich)
Tel. +41 44 733 46 46
e-mail: harry.welten(at)cytos.com
www.cytos.com
End of Corporate News
---------------------------------------------------------------------
28.07.2011 News transmitted by EquityStory AG.
The issuer is responsible for the contents of the release.
EquityStory publishes regulatory releases, media releases on the
capital market and press releases.
The EquityStory Group distributes authentic and real-time financial
news for over 1'300 listed companies.
The Swiss news archive can be found at
http://www.equitystory.ch/nachrichten
---------------------------------------------------------------------
Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Switzerland
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: info(at)cytos.com
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
Swiss Security Number: -
Listed: Regulierter Markt in SIX; Freiverkehr in
Berlin, München, Stuttgart; Open Market in
Frankfurt
End of News EquityStory AG News-Service
---------------------------------------------------------------------
133436 28.07.2011
Datum: 28.07.2011 - 07:00 Uhr
Sprache: Deutsch
News-ID 38587
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 217 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Cytos Biotechnology Second Quarter Report 2011"
steht unter der journalistisch-redaktionellen Verantwortung von
Cytos Biotechnology AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
